Skip to main content

Immunotherapy

Pancreatic Cancer: Review of the Current and Investigational Drug Landscape
Kevin H. Pang, PharmD; Valassia Antigone Theocharides; Yuxi Lei; Shivani K. Rana, BS; Richa K. Rana, BS; Mark H. Mansour; Meghana K. Ganjam; Jennifer Ahmed, PharmD
Read More
Complete Pathologic Response to Pembrolizumab in a Patient with Cutaneous Angiosarcoma: Case Report
Michael J. Nathenson, MD, and Jason L. Hornick, MD, PhD
Read More
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies
Christopher Sinoimeri, PharmD; Bryan Do, PharmD, BCOP; Sheree Chen, PharmD, BCOP
Read More
Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma
Read More
The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence
Abstract #CR10
Read More
Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis
Katherine P. Morgan, PharmD, BCOP, CPP; Yujiao Sun, PharmD; Allison Deal; Jared Weiss, MD; Amber Cipriani, PharmD, BCOP
Read More
Progression of Metastatic, PD-L1–Positive, Ampullary Carcinoma with a Treatment Holiday from Off-Label Use of Pembrolizumab Therapy
Hayley Heers, PharmD, BCPS; Amin Seyedkazemi, DO; Natalee Tanner, PharmD, BCOP; Madappa Kundranda, MD, PhD, FACP
Read More
The Intersection of Immunotherapy and Targeted Therapy in Lung Cancer
Meg Barbor, MPH
Read More
Rapid Onset of Severe Transaminitis in a Patient with Non–Small-Cell Lung Cancer After First Dose of Nivolumab 480 mg
Matthew Stankowicz, PharmD, BS; Megan Banaszynski, PharmD, BCOP; Russell Crawford, RPh, BCOP
Read More
Meeting Highlights
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome
Read More
Page 2 of 4
Results 11 - 20 of 35